Kimberly Bravo
Family · Hilliard, FLNPI 1447270400
Payments from drug & device makers
Across 260 payments — averaging $29.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$976
- GSK$961
- Abbott$545
- AbbVie$475
- Sanofi-aventis U.S. LLC$375
- plus $2K from 30 others
What the payments were for
- Food & beverage$7,60599%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $1,923 |
| Novo Nordisk | 25 | $976 |
| GSK | 34 | $961 |
| Abbott | 18 | $545 |
| AbbVie | 19 | $475 |
| Sanofi-aventis U.S. LLC | 19 | $375 |
| Bayer | 17 | $350 |
| Johnson & Johnson | 14 | $245 |
| Exact Sciences | 13 | $230 |
| Otsuka America Pharmaceutical, Inc. | 8 | $189 |
| Medtronic | 2 | $183 |
| Lilly USA, LLC | 14 | $179 |
| Stryker | 1 | $140 |
| Edwards Lifesciences | 1 | $105 |
| Boehringer Ingelheim | 5 | $93 |
| Dexcom, Inc. | 4 | $76 |
| Novartis | 3 | $63 |
| Mannkind Corporation | 1 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $57 |
| Corcept Therapeutics | 2 | $45 |
| Astellas Pharma US Inc | 3 | $45 |
| Amgen | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $39 |
| Merck | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Noven Therapeutics, LLC | 1 | $25 |
| Vifor Pharma, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Smith+Nephew | 1 | $20 |
| Pfizer | 1 | $19 |
| Grifols USA, LLC | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$706
- BREZTRI$490
- RYBELSUS$345
- FREESTYLE LIBRE 3$299
- AIRSUPRA$238
- Ozempic$230
- LIMFLOW SYSTEM$140
- FreeStyle Libre 2$135
- AREXVY$125
- TEZSPIRE$125
- VRAYLAR$125
- Wegovy$118
- TRELEGY ELLIPTA$111
- LINQ II$109
- Edwards SAPIEN 3 Transcatheter Heart Valve$105
How this compares
$7,664 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 53 | $69,191 |
| OzempicSemaglutide | 58 | $68,285 |
| EliquisApixaban | 54 | $49,485 |
| FarxigaDapagliflozin Propanediol | 48 | $46,608 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $34,817 |
| XareltoRivaroxaban | 42 | $34,620 |
| TrulicityDulaglutide | 25 | $30,164 |
| JardianceEmpagliflozin | 17 | $27,222 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 22 | $18,252 |
| MyrbetriqMirabegron | 17 | $12,219 |
| DapagliflozinDapagliflozin Propanediol | 13 | $7,243 |
| Gabapentin | 183 | $2,982 |
| Diclofenac Sodium | 27 | $2,367 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 113 | $2,292 |
| Omeprazole | 152 | $2,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $179 | $99,35578 claims |
| Novo NordiskOzempic | $976 | $68,28558 claims |
| PfizerEliquis | $19 | $49,48554 claims |
| AstraZenecaFarxiga | $1,923 | $46,60848 claims |
| GSKTrelegy Ellipta | $961 | $34,81747 claims |
| Johnson & JohnsonXarelto | $245 | $34,62042 claims |
| Boehringer IngelheimJardiance | $93 | $27,22217 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $375 | $18,25222 claims |
| Astellas Pharma US IncMyrbetriq | $45 | $12,21917 claims |
| AbbVieSynthroid | $475 | $1,16712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Hilliard
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.